Rhythm Biosciences Ltd (ASX: RHY) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Rhythm Biosciences Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $248.34 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 214.08 million
Earnings per share -0.044
Dividend per share N/A
Year To Date Return -24.52%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Rhythm Biosciences Ltd (ASX: RHY)
Latest News

asx share price growth represented by rocket flying up increasing bar chart.
Healthcare Shares

Here’s why the Rhythm (ASX:RHY) share price is soaring 8% today

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the run following the company’s strategic update to FY22. Here's…

Read more »

Monadelphous share price rio tinto A small rocket take off from a laptop, indicating a share price surge
Healthcare Shares

Rhythm (ASX:RHY) share price surges 10% on ColoSTAT results

The Rhythm Biosciences Ltd (ASX: RHY) share price is surging 10% today following the release of its ColoSTAT results. We…

Read more »

woman in lab coat conducting testing representing biotech
Share Market News

What is going on with the Rhythm (ASX:RHY) share price today?

The Rhythm Biosciences Ltd (ASX: RHY) share price is recovering after slipping this morning despite announcing a positive update.

Read more »

ASX bank profit upgrade Red rocket and arrow boosting up a share price chart
Share Market News

The Rhythm (ASX:RHY) share price surges on cancer testing milestone

The Rhythm Biosciences Ltd (ASX: RHY) share price has surged 6% higher on Tuesday as the company takes a step…

Read more »

Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares
Share Market News

Which ASX healthcare shares saw the biggest gains in February?

ASX healthcare shares struggled to make headway in February. Here are the 2 companies that managed to come out on…

Read more »

Questioning asx share price represented by women with virtual question marks above her head
Share Market News

What’s happening with the Rhythm (ASX:RHY) share price today?

The Rhythm Biosciences Ltd (ASX: RHY) share price is sinking today, despite announcing a positive update to its ColoSTAT trial…

Read more »

hand on touch screen lit up by a share price chart moving higher
Share Market News

Why the Rhythm (ASX:RHY) share price again reached a new all-time record today

The Rhythm Biosciences Ltd (ASX: RHY) has risen to another all-time high record following the update on the initial manufacturing…

Read more »

medical asx share price represented by doctor giving thumbs up
Share Market News

Here’s why the Rhythm (ASX:RHY) share price hit an all-time high today

Shares in Rhythm Biosciences Ltd (ASX: RHY) are soaring higher during early-afternoon trade. This comes after the company announced it…

Read more »

RHY ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Rhythm Biosciences Ltd

Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. Geographically, the company operates only in Australia.

RHY Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
06 Jul 2022 $1.16 $-0.01 -0.85% 135,129 $1.21 $1.21 $1.16
05 Jul 2022 $1.17 $-0.02 -1.68% 7,383 $1.20 $1.21 $1.17
04 Jul 2022 $1.19 $-0.01 -0.83% 62,384 $1.21 $1.21 $1.18
01 Jul 2022 $1.20 $0.05 4.35% 48,574 $1.15 $1.20 $1.15
30 Jun 2022 $1.15 $0.00 0.00% 65,036 $1.16 $1.16 $1.13
29 Jun 2022 $1.15 $-0.02 -1.71% 66,684 $1.17 $1.17 $1.15
28 Jun 2022 $1.17 $0.01 0.86% 42,648 $1.15 $1.17 $1.14
27 Jun 2022 $1.16 $0.05 4.50% 117,604 $1.13 $1.21 $1.13
24 Jun 2022 $1.11 $0.06 5.71% 272,925 $1.06 $1.11 $1.04
23 Jun 2022 $1.05 $-0.01 -0.94% 167,269 $1.07 $1.07 $1.03
22 Jun 2022 $1.06 $-0.06 -5.36% 85,755 $1.12 $1.12 $1.06
21 Jun 2022 $1.12 $0.06 5.66% 79,881 $1.06 $1.12 $1.04
20 Jun 2022 $1.06 $0.01 0.95% 97,756 $1.06 $1.08 $1.04
17 Jun 2022 $1.05 $-0.02 -1.87% 216,327 $1.06 $1.06 $1.04
16 Jun 2022 $1.07 $-0.02 -1.83% 107,722 $1.11 $1.11 $1.07
15 Jun 2022 $1.10 $0.00 0.00% 100,831 $1.10 $1.12 $1.08
14 Jun 2022 $1.10 $-0.10 -8.40% 305,732 $1.16 $1.16 $1.08
10 Jun 2022 $1.19 $-0.01 -0.83% 163,604 $1.20 $1.22 $1.17
09 Jun 2022 $1.20 $0.00 0.00% 328,006 $1.20 $1.20 $1.16
08 Jun 2022 $1.20 $0.03 2.56% 114,039 $1.21 $1.22 $1.19
07 Jun 2022 $1.17 $-0.04 -3.32% 54,931 $1.19 $1.19 $1.17

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
25 Nov 2021 Otto Buttula Issued 2 $3,710,000
Issue of options.
25 Nov 2021 Trevor Lockett Issued 500 $927,500
Issue of options.
25 Nov 2021 Louis (Lou) Panaccio Issued 150 $278,250
Issue of options.
25 Nov 2021 Eduardo Vom Issued 150 $278,250
Issue of options.
09 Sep 2021 Trevor Lockett Issued 4 $4,000
Rights issue.
09 Sep 2021 Trevor Lockett Issued 4 $3,400
Rights issue.
09 Sep 2021 Eduardo Vom Issued 88 $88,818
Rights issue.
09 Sep 2021 Eduardo Vom Issued 28 $24,139
Rights issue.
09 Sep 2021 Eduardo Vom Issued 60 $51,354
Rights issue.
09 Sep 2021 Louis (Lou) Panaccio Issued 20 $17,000
Rights issue.
09 Sep 2021 Louis (Lou) Panaccio Issued 20 $20,000
Rights issue.
09 Sep 2021 Otto Buttula Issued 685 $582,251
Rights issue.
09 Sep 2021 Otto Buttula Issued 685 $685,002
Rights issue.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Otto Leslie Steven Buttula Executive ChairmanExecutive Director Oct 2019
Mr Buttula has had experience in investment research, funds management, information and biotechnologies and has held directorships in a number of public companies. Mr Buttula's executive experience includes co-founder and CEO and Managing Director of IWL Limited, an online financial services company that listed on the ASX in 1999. Mr Buttula also founded and was Managing Director of Investors Mutual, prior to which he was a co-founder and director of Lonsdale Securities Limited. Following his completion of executive duties, Mr Buttula was Non-Executive Chairman of platform and stockbroking provider Investorfirst Limited and led the acquisition of HUB24 Limited (ASX: HUB). More recently, he served on the Board as a non-executive director and Head of Audit and Risk at Imugene Limited (ASX: IMU) between 2014 and 2016.
Mr Louis (Lou) James Panaccio Non-Executive Director Aug 2017
Mr Panaccio has experience in business and healthcare services. Lou is currently on the boards of ASX listed companies Sonic Healthcare Limited and Avita Therapeutics, Inc. Lou is also on the board of Unison Housing Limited. He has more than twenty years of experience as a board member of both public and private, for profit and not for profit companies. Previously, Lou was the CEO of Melbourne Pathology and Monash IVF, and also executive Chairman of Health Networks Australia.
Dr Trevor John Lockett Executive DirectorTechnical Director Jun 2017
Mr Lockett has over 30 years of research experience, at the CSIRO, Trevor has led large, multidisciplinary research efforts in the areas of prostate cancer gene therapy, colorectal cancer prevention and the promotion of gastrointestinal health. In his role as Theme Leader, Colorectal Cancer and Gut Health, Trevor oversaw the research efforts leading to the technology that is to become ColoSTAT
Mr Glenn Gilbert Chief Executive OfficerManaging Director Dec 2021
--
Mr Eduardo Vom Non-Executive Director Jun 2020
Mr Vom has over 20 years of experience in technology and development and commercialisation in the biotech industry, having held leadership roles at cancer diagnostics manufacturer Vision BioSystems and molecular diagnostics company Genetic Technologies. He currently serves as a non-executive director with privately owned health and wellbeing companies and has experience in digital healthcare, management of multi discipline projects, business strategy and technology commercialisation.
Dr Rachel David Non-Executive Director Dec 2021
Dr David is an experienced senior health and financial services sector executive with understanding of the complex interplay between government, business, media and the community. Her career has spanned over 25 years in healthcare, particularly relating to evidence-based practice and access to new technologies. She is currently the Chief Executive Officer (CEO) of Private Healthcare Australia (PHA). This includes the two major listed companies, Medibank and nib. Prior roles include Senior Director Government Affairs, Policy and Market Access for Johnson & Johnson, senior roles within McKinsey, CSL and Pfizer (formerly Wyeth). Further, Dr David has held direct Government roles within the Office of the Federal Minister for Health and Ageing.
Ms Andrea Steele Company SecretaryGeneral Counsel Feb 2022
-
Andrea Steele Company SecretaryGeneral Counsel
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Webinvest Pty Ltd 16,666,667 8.24%
Newfound Investments Pty Ltd 10,733,333 5.31%
Ferndale Securities Pty Ltd 10,100,000 4.99%
Loumea Investment Pty Ltd 9,915,000 4.90%
Northern Star Nominees Pty Ltd 7,200,000 3.56%
Mrs Sarah Cameron 6,300,000 3.12%
Rojo Nero Capital Pty Ltd 4,166,668 2.06%
Giokir Pty Ltd 3,400,000 1.68%
Mr Hsien Michael Soo 3,224,783 1.59%
Jawaf Enterprises Pty Ltd 3,150,000 1.56%
Commonwealth Scientific & Industrial Research Organisation 2,500,000 1.24%
Mr Daniel Eddington & Mrs Julie Eddington 2,460,000 1.22%
Ms Natalie Louise Patterson 2,416,666 1.19%
Garnsworthy Pension Fund Pty Ltd 2,250,000 1.11%
Dr Gavin James Shepherd & Mrs Catherine Shepherd 2,000,000 0.99%
E & W Nominee Pty Ltd 2,000,000 0.99%
Dc & Pc Holdings Pty Ltd 1,750,000 0.87%
Mr Richard Stanley De Ravin 1,600,000 0.79%
Dr Paul Maxwell Miller & Mrs Louise Monique Miller 1,509,188 0.75%
HSBC Custody Nominees (Australia) Limited 1,491,945 0.74%

Profile

since

Note